November 6, 2026
Big changes are happening in the world of peptide wellness, and we're excited to share an important update with our community!
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced a new enforcement discretion policy involving six specific peptides. Published in the Federal Register on October 30, the policy outlines a potential pathway for qualifying 503A compounding pharmacies and licensed medical professionals to prepare certain peptide medications under defined conditions.
For patients interested in personalized wellness and provider-guided peptide therapy, this represents a noteworthy regulatory development.
But what exactly changed, which peptides are included, and what does it mean for you?
Let's break it down.
Peptides are short chains of amino acids, the building blocks of proteins. They occur naturally throughout the body and participate in a variety of biological processes.
Scientists also study synthetic peptides to better understand their potential medical applications.
While some peptide medications have received FDA approval for specific uses, many other peptides remain investigational. Their potential benefits, risks, and long-term effects are still being studied.
HHS introduced an interim enforcement discretion policy addressing certain compounded medications containing six specific peptide ingredients.
Under this policy, federal authorities intend to refrain from specified enforcement actions against qualifying 503A compounders when all applicable conditions are met.
This creates a potential pathway for certain peptides to be prepared through licensed pharmacies with appropriate medical oversight.
An important distinction: This policy does not mean the six peptides are FDA-approved, automatically legal in every circumstance, or proven safe and effective. It also does not mean every pharmacy can immediately offer them.
The new policy specifically addresses the following peptides:
BPC-157 is a synthetic peptide that has attracted research interest involving biological processes associated with tissue repair and inflammation.
TB-500 is a synthetic peptide associated with research into cellular movement, tissue responses, and repair-related biological processes.
KPV is a short peptide consisting of three amino acids. Researchers have investigated its potential interactions with inflammatory pathways, including in laboratory and preclinical studies.
MOTS-C is a mitochondrial-derived peptide studied for its involvement in cellular signaling and metabolic processes.
Epitalon is a synthetic peptide that has been studied in connection with cellular aging and related biological pathways.
Semax is a synthetic peptide investigated for its effects on neurological signaling and other nervous system processes.
The HHS policy identifies specific ingredient forms and administration routes:
A 503A compounding pharmacy prepares customized medications for individual patients pursuant to valid prescriptions and applicable legal requirements.
Unlike mass-manufactured, FDA-approved medications, compounded medications are prepared to address individual patient needs.
Compounding pharmacies must comply with applicable pharmacy laws and standards. However, compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality before marketing.
The new HHS policy applies only to qualifying 503A compounding arrangements that satisfy its specified conditions.
At Above Wellness, personalized care and responsible pharmacy sourcing have always been central to our approach.
We exclusively partner with licensed 503A compounding pharmacies and emphasize provider-guided treatment decisions.
The new HHS policy creates opportunities to evaluate additional peptide therapies within a framework involving licensed medical professionals and qualifying pharmacies.
Our team is monitoring these developments and working with our pharmacy partners to understand which formulations may meet the updated requirements.
Any treatment offered through Above Wellness must satisfy applicable regulations, pharmacy requirements, and individualized prescribing decisions.
Our goal remains the same: to help patients make informed wellness decisions through education, transparency, and appropriate medical oversight.
Above Wellness is proud to be LegitScript Certified.
LegitScript is an independent certification organization that evaluates healthcare businesses against applicable certification standards, including relevant regulatory and operational requirements.
Following the HHS announcement, LegitScript updated its certification review approach effective November 2, 2026.
Under the updated approach, offering a qualifying peptide covered by the HHS policy does not, by itself, prevent a healthcare business from maintaining certification, provided all applicable requirements are met.
This is an important development for businesses like Above Wellness that prioritize compliant, provider-guided wellness services.
LegitScript certification does not mean that a particular medication is FDA-approved or that every individual offering has received separate regulatory approval.
No.
The HHS announcement is an enforcement discretion policy, not an FDA drug approval.
The six peptides have not been added to the final 503A bulk drug substances list through this announcement.
The policy is interim, may be revised or withdrawn, and does not establish that these peptides are safe or effective for particular medical conditions.
Patients should also understand that research interest does not necessarily translate into proven clinical benefits.
As the regulatory landscape continues to evolve, additional guidance may clarify how qualifying pharmacies and healthcare businesses can implement the policy.
The FDA may also consider future rulemaking concerning the six peptide ingredients.
At Above Wellness, we'll continue monitoring updates, communicating with our pharmacy partners, and sharing reliable educational information with our patients.
Whether you're new to peptide wellness or already exploring provider-guided treatment options, understanding the science and regulatory requirements is an important first step.
Above Wellness offers personalized wellness services supported by medical evaluation, responsible pharmacy partnerships, and ongoing patient education.
Have questions about our current peptide therapy options?
Visit www.abovewellnessofficial.com to explore our services and learn more about our approach to personalized wellness.
Written by
1. U.S. Department of Health and Human Services (HHS)
Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.
Published October 30, 2026.
https://www.federalregister.gov/d/2026-22192
2. LegitScript
HHS's Peptide Compounding Policy: What Healthcare Businesses Need to Know.
Published November 2, 2026.
Above Wellness
GLP-1 medications may do more than support weight loss. New research is exploring their potential role in brain health, cognitive function, and healthy aging.
Above Wellness
Prescription glutathione injection and nasal spray options through Above Wellness. Learn how glutathione supports antioxidant balance, detox pathways, and cellular health.
Above Wellness
PT-141 for libido helps restore sexual desire and balance disrupted by stress, toxins, and hormonal imbalances. It reactivates the brain’s arousal pathways to reconnect mind and body naturally.
Above Wellness operates as a connecting intermediary between customers and licensed healthcare professionals, facilitating the exchange of information and services. We do not operate as a pharmacy ourselves. All products are prescription only and require provider approval.
Payment options through Cherry Technologies, Inc. are issued by its financing partners: https://withcherry.com/financing_partners
© 2026 Above Wellness. All rights reserved.
